Seroatlas · Human Serome Atlas

MPO

Myeloperoxidase

Also known as: PERM_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P05164
Gene
MPO
Ensembl
ENSG00000005381
Chromosome
17
Canonical length
745 aa
Protein class
Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Vesicles
Secretome location
Intracellular and membrane
Quaternary structure
Homodimer

OverviewNCBI Gene

Myeloperoxidase (MPO) is a heme protein synthesized during myeloid differentiation that constitutes the major component of neutrophil azurophilic granules. Produced as a single chain precursor, myeloperoxidase is subsequently cleaved into a light and heavy chain. The mature myeloperoxidase is a tetramer composed of 2 light chains and 2 heavy chains. This enzyme produces hypohalous acids central to the microbicidal activity of neutrophils. [provided by RefSeq, Nov 2014]

Canonical amino-acid sequenceUniProt

745 residues, UniProt reviewed canonical sequence.

>P05164|MPO
     1  MGVPFFSSLR CMVDLGPCWA GGLTAEMKLL LALAGLLAIL ATPQPSEGAA PAVLGEVDTS
    61  LVLSSMEEAK QLVDKAYKER RESIKQRLRS GSASPMELLS YFKQPVAATR TAVRAADYLH
   121  VALDLLERKL RSLWRRPFNV TDVLTPAQLN VLSKSSGCAY QDVGVTCPEQ DKYRTITGMC
   181  NNRRSPTLGA SNRAFVRWLP AEYEDGFSLP YGWTPGVKRN GFPVALARAV SNEIVRFPTD
   241  QLTPDQERSL MFMQWGQLLD HDLDFTPEPA ARASFVTGVN CETSCVQQPP CFPLKIPPND
   301  PRIKNQADCI PFFRSCPACP GSNITIRNQI NALTSFVDAS MVYGSEEPLA RNLRNMSNQL
   361  GLLAVNQRFQ DNGRALLPFD NLHDDPCLLT NRSARIPCFL AGDTRSSEMP ELTSMHTLLL
   421  REHNRLATEL KSLNPRWDGE RLYQEARKIV GAMVQIITYR DYLPLVLGPT AMRKYLPTYR
   481  SYNDSVDPRI ANVFTNAFRY GHTLIQPFMF RLDNRYQPME PNPRVPLSRV FFASWRVVLE
   541  GGIDPILRGL MATPAKLNRQ NQIAVDEIRE RLFEQVMRIG LDLPALNMQR SRDHGLPGYN
   601  AWRRFCGLPQ PETVGQLGTV LRNLKLARKL MEQYGTPNNI DIWMGGVSEP LKRKGRVGPL
   661  LACIIGTQFR KLRDGDRFWW ENEGVFSMQQ RQALAQISLP RIICDNTGIT TVSKNNIFMS
   721  NSYPRDFVNC STLPALNLAS WREAS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MPO can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.23
Highest tissue expression
3,250 nTPM

Expression across tissuesHPA

Tissue

  • bone marrow: 3,250 nTPM
  • spleen: 21 nTPM
  • salivary gland: 9.9 nTPM
  • lung: 8.1 nTPM
  • thymus: 6.9 nTPM
  • skin: 3.7 nTPM

Single-cell type

  • monocyte progenitors: 2,629 nCPM
  • neutrophil progenitors: 2,272 nCPM
  • erythrocytes: 40 nCPM
  • hematopoietic stem cells: 32 nCPM
  • megakaryocytes: 25 nCPM
  • megakaryocyte-erythroid progenitors: 18 nCPM

Immune cell

  • total PBMC: 6.3 nTPM
  • classical monocyte: 1.2 nTPM
  • myeloid DC: 0.7 nTPM
  • intermediate monocyte: 0.6 nTPM
  • neutrophil: 0.1 nTPM
  • non-classical monocyte: 0.1 nTPM

Brain region

  • midbrain: 0.5 nTPM
  • cerebral cortex: 0.4 nTPM
  • hypothalamus: 0.4 nTPM
  • medulla oblongata: 0.4 nTPM
  • pons: 0.4 nTPM
  • thalamus: 0.4 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about MPO.

Disease | AllUniProt

Conditions MPO is implicated in, by any mechanism.

Disease | GeneticClinVar

16 pathogenic / likely-pathogenic of 159 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on MPO was assayed in.

Disease | AutoantibodyPubMed

Conditions in which antibodies against MPO are reported. Each links to that disease's full target list.

Showing 20 of 49 — disease pages carrying at least 10 antigens.

ReferencesPubMed · IEDB

Publications for MPO from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

612 publications

Show 20 more of 612 total

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.15
gnomAD pLI
0
gnomAD missense Z
0.32
DepMap mean gene effect
-0.13
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MPO in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MPO as an antibody target. Whether an autoantibody or antibody against MPO could matter depends on whether native MPO is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MPO is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MPO as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/MPO. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...